Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends

Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends

"IntroductionWith Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing. However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds.ScopeOverview of drivers and resistors of licensing deals, with recommendations and case study analysis of how companies can optimize the licensing process Examination of how to successfully navigate the licensing process, with analysis of how companies are looking to modernize their licensing strategies Analysis of key product deals during 2005–06, analyzing trends for in-licensing, co-development, out-licensing and marketing & promotion deals Assessment of drug discovery deals and technology deals, made by the top 20 pharmaceutical companies during 2005–06HighlightsThe constant demand for late-stage product candidates has led to spiraling deal costs. Therefore companies are now looking to in-license earlier-stage compounds, demonstrated by the recent resurgence in preclinical and Phase I licensing deals made by the top 20 pharmaceutical companies. Companies facing patent expiries of key revenue drivers between 2006–12 have in-licensed products to counteract the ensuing sales erosion. However, this tactic is not expected produce a positive growth in the short term for all companies, although it will at least offset part of their revenue deficit. During 2005–06, Novartis was the leading dealmaker, followed by Bayer-Schering, Roche, and J&J, with the top six companies responsible for 50% of all deals made by the leading 20 companies.Reasons to PurchaseUnderstand the opportunities and threats companies face when licensing their products, and the resultant strategies some companies are employing Identify suitable Pharma to target when considering licensing partners for your technologies and products Benchmark the success of your licensing strategy in order to improve future deal making success"

14-Nov-07 Format: PDF & SlidePack Pages: 162
Table of Contents
Price: $15,200.00 / €10,168.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions